Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL-008 is a preclinical-stage therapeutic candidate being developed by Bloom Science for the treatment of Alzheimer's disease. It is designed to modulate neuroinflammation, a key driver of neurodegeneration, through the gut-brain axis. Bloom Science utilizes a platform focused on identifying specific microbes and metabolites that influence neurological health. BL-008 is categorized as a live biotherapeutic product (LBP), intended to regulate systemic immune and metabolic pathways to potentially slow the progression of Alzheimer's pathology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BL-008.